MorphoSys AG (ETR:MOR) has been given a €62.00 ($72.94) price objective by stock analysts at J P Morgan Chase & Co in a note issued to investors on Friday. The firm presently has a “neutral” rating on the stock.

A number of other research firms have also recently issued reports on MOR. Commerzbank Ag set a €76.00 ($89.41) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, July 24th. Independent Research GmbH set a €77.00 ($90.59) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Monday, July 24th. Berenberg Bank set a €68.00 ($80.00) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Friday, July 14th. Finally, HSBC Holdings plc set a €59.00 ($69.41) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Friday, July 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of €69.57 ($81.85).

MorphoSys AG (ETR MOR) traded down 1.975% during midday trading on Friday, reaching €59.998. 5,408 shares of the company’s stock were exchanged. The stock’s market capitalization is €1.73 billion. The stock’s 50-day moving average is €62.87 and its 200-day moving average is €57.10. MorphoSys AG has a 12-month low of €35.72 and a 12-month high of €70.90.

COPYRIGHT VIOLATION NOTICE: “MorphoSys AG (MOR) Given a €62.00 Price Target by J P Morgan Chase & Co Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/06/morphosys-ag-mor-given-a-62-00-price-target-by-j-p-morgan-chase-co-analysts.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.